PD-L1 immune suppression in cancer: Tumor cells or host cells?

Four recent publications reported the role of PD-L1 expression on host versus malignant cells within the tumor for PD-1/PD-L1 checkpoint blockade therapy. All four research groups harmoniously report: PD-L1 expressed by both host as well as tumor cells are capable of suppressing T cell functions. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleinovink, Jan Willem, van Hall, Thorbald, Ossendorp, Ferry, Fransen, Marieke F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543902/
https://www.ncbi.nlm.nih.gov/pubmed/28811961
http://dx.doi.org/10.1080/2162402X.2017.1325982
_version_ 1783255216178593792
author Kleinovink, Jan Willem
van Hall, Thorbald
Ossendorp, Ferry
Fransen, Marieke F.
author_facet Kleinovink, Jan Willem
van Hall, Thorbald
Ossendorp, Ferry
Fransen, Marieke F.
author_sort Kleinovink, Jan Willem
collection PubMed
description Four recent publications reported the role of PD-L1 expression on host versus malignant cells within the tumor for PD-1/PD-L1 checkpoint blockade therapy. All four research groups harmoniously report: PD-L1 expressed by both host as well as tumor cells are capable of suppressing T cell functions. Thus, checkpoint therapy can be effective, if malignant cells do not express PD-L1.
format Online
Article
Text
id pubmed-5543902
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-55439022017-08-15 PD-L1 immune suppression in cancer: Tumor cells or host cells? Kleinovink, Jan Willem van Hall, Thorbald Ossendorp, Ferry Fransen, Marieke F. Oncoimmunology Author's View Four recent publications reported the role of PD-L1 expression on host versus malignant cells within the tumor for PD-1/PD-L1 checkpoint blockade therapy. All four research groups harmoniously report: PD-L1 expressed by both host as well as tumor cells are capable of suppressing T cell functions. Thus, checkpoint therapy can be effective, if malignant cells do not express PD-L1. Taylor & Francis 2017-05-12 /pmc/articles/PMC5543902/ /pubmed/28811961 http://dx.doi.org/10.1080/2162402X.2017.1325982 Text en © 2017 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Kleinovink, Jan Willem
van Hall, Thorbald
Ossendorp, Ferry
Fransen, Marieke F.
PD-L1 immune suppression in cancer: Tumor cells or host cells?
title PD-L1 immune suppression in cancer: Tumor cells or host cells?
title_full PD-L1 immune suppression in cancer: Tumor cells or host cells?
title_fullStr PD-L1 immune suppression in cancer: Tumor cells or host cells?
title_full_unstemmed PD-L1 immune suppression in cancer: Tumor cells or host cells?
title_short PD-L1 immune suppression in cancer: Tumor cells or host cells?
title_sort pd-l1 immune suppression in cancer: tumor cells or host cells?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543902/
https://www.ncbi.nlm.nih.gov/pubmed/28811961
http://dx.doi.org/10.1080/2162402X.2017.1325982
work_keys_str_mv AT kleinovinkjanwillem pdl1immunesuppressionincancertumorcellsorhostcells
AT vanhallthorbald pdl1immunesuppressionincancertumorcellsorhostcells
AT ossendorpferry pdl1immunesuppressionincancertumorcellsorhostcells
AT fransenmariekef pdl1immunesuppressionincancertumorcellsorhostcells

Ejemplares similares